View Cart  

Mylan Sues FDA to Claim First-Filer Status on Provigil ANDA from Teva

In the latest patent commotion over Provigil, Mylan Pharmaceuticals is suing the FDA over its recent decision to grant Teva sole first-filer status for a generic of the sleep disorder drug, saying the FDA  overlooked an anti-competitive legal loophole.

To View This Article:


Subscribe To Generic Line

Buy This Article Now

Add this article to your cart for $40.00